Catalyst Pharmaceuticals (CPRX) 10-K15 Mar 232022 FY Annual reportFinancial data

Company Profile

Cover Page

Cover Page - USD ($)	12 Months Ended
Cover Page - USD ($)	Dec. 31, 2022	Mar. 13, 2023	Jun. 30, 2022
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Registrant Name	CATALYST PHARMACEUTICALS, INC
Entity Central Index Key	0001369568
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Accelerated Filer
Trading Symbol	CPRX
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Address, State or Province	FL
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		105,654,395
Entity Tax Identification Number	76-0837053
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	355 Alhambra Circle
Entity Address, Address Line Two	Suite 801
Entity Address, City or Town	Coral Gables
Entity Address, Postal Zip Code	33134
City Area Code	305
Local Phone Number	420-3200
Document Annual Report	true
Document Transition Report	false
Entity File Number	001-33057
Entity Public Float			$ 665,590,948
ICFR Auditor Attestation Flag	true
Auditor Name	GRANT THORNTON LLP
Auditor Firm ID	248
Auditor Location	Miami, Florida

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current Assets:
Cash and cash equivalents	$ 298,395	$ 171,445
Short-term investments	0	19,821
Accounts receivable, net	10,439	6,619
Inventory	6,805	7,870
Prepaid expenses and other current assets	5,158	4,351
Total current assets	320,797	210,106
Operating lease right-of-use asset	2,770	3,017
Property and equipment, net	847	959
License and acquired intangibles, net	32,471
Deferred tax assets, net	18,736	23,697
Deposits	9	9
Total assets	375,630	237,788
Current Liabilities:
Accounts payable	3,975	2,768
Accrued expenses and other liabilities	53,613	24,295
Total current liabilities	57,588	27,063
Operating lease liability, net of current portion	3,557	3,894
Other non-current liabilities	14,064
Total liabilities	75,209	30,957
Commitments and contingencies (Note 12)
Stockholders' equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized: none issued and outstanding at December 31, 2022 and 2021	0	0
Common stock, $0.001 par value, 200,000,000 shares authorized; 105,263,031 shares and 102,992,913 shares issued and outstanding at December 31, 2022 and 2021, respectively	105	103
Additional paid-in capital	250,430	233,186
Retained earnings (accumulated deficit)	49,862	(26,310)
Accumulated other comprehensive income (loss)	24	(148)
Total stockholders' equity	300,421	206,831
Total liabilities and stockholders' equity	$ 375,630	$ 237,788

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	105,263,031	102,992,913
Common stock, shares outstanding	105,263,031	102,992,913

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues:
Total revenues	$ 214,203	$ 140,833	$ 119,073
Operating costs and expenses:
Cost of sales	34,393	21,884	17,039
Research and development	19,789	16,936	16,497
Selling, general and administrative	58,183	49,628	44,234
Total operating costs and expenses	112,365	88,448	77,770
Operating income	101,838	52,385	41,303
Other income, net	2,881	282	587
Net income before income taxes	104,719	52,667	41,890
Income tax provision (benefit)	21,640	13,185	(33,093)
Net income	$ 83,079	$ 39,482	$ 74,983
Net income per share:
Basic	$ 0.8	$ 0.38	$ 0.72
Diluted	$ 0.75	$ 0.37	$ 0.71
Weighted average shares outstanding:
Basic	103,374,606	103,379,349	103,512,913
Diluted	111,375,631	107,795,585	106,242,273
Net income	$ 83,079	$ 39,482	$ 74,983
Other comprehensive income:
Unrealized gain (loss) on available-for-sale securities, net of tax of ($54), $46 and $0, respectively	172	(179)	22
Comprehensive income	83,251	39,303	75,005
Product revenue, net [Member]
Revenues:
Total revenues	213,938	137,997	118,790
License and other revenue [Member]
Revenues:
Total revenues	$ 265	$ 2,836	$ 283

CONSOLIDATED STATEMENTS OF OP_2

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement of Comprehensive Income [Abstract]
Net of tax impact	$ (54)	$ 46	$ 0

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Gain (Loss) [Member]
Beginning Balance at Dec. 31, 2019	$ 87,630	$ 104	$ 216,205	$ (128,688)	$ 9
Beginning Balance (shares) at Dec. 31, 2019		103,397,000
Issuance of stock options for services	5,694		5,694
Exercise of stock options for common stock	758	$ 0	758
Exercise of stock options for common stock (shares)		282,000
Amortization of restricted stock for services	567		567
Issuance of common stock upon vesting of restricted stock units, net	(56)		(56)
Issuance of common stock upon vesting of restricted stock units, net (Share)		103,000
Other comprehensive gain (loss)	22				22
Net income	74,983			74,983
Ending Balance at Dec. 31, 2020	169,598	$ 104	223,168	(53,705)	31
Ending Balance (shares) at Dec. 31, 2020		103,782,000
Issuance of stock options for services	5,550		5,550
Exercise of stock options for common stock	4,099	$ 1	4,098
Exercise of stock options for common stock (shares)		1,328,000
Amortization of restricted stock for services	523		523
Issuance of common stock upon vesting of restricted stock units, net	(153)		(153)
Issuance of common stock upon vesting of restricted stock units, net (Share)		91,000
Repurchase of common stock (shares)		(2,208,292)
Repurchase of common stock	(12,089)	$ (2)		(12,087)
Other comprehensive gain (loss)	(179)				(179)
Net income	39,482			39,482
Ending Balance at Dec. 31, 2021	206,831	$ 103	233,186	(26,310)	(148)
Ending Balance (shares) at Dec. 31, 2021		102,993,000
Issuance of stock options for services	6,346		6,346
Exercise of stock options for common stock	$ 9,569	$ 2	9,567
Exercise of stock options for common stock (shares)	3,172,342	3,172,000
Amortization of restricted stock for services	$ 1,561		1,561
Issuance of common stock upon vesting of restricted stock units, net	(230)		(230)
Issuance of common stock upon vesting of restricted stock units, net (Share)		98,000
Repurchase of common stock (shares)		(1,000,000)
Repurchase of common stock	(6,907)			(6,907)
Other comprehensive gain (loss)	172				172
Net income	83,079			83,079
Ending Balance at Dec. 31, 2022	$ 300,421	$ 105	$ 250,430	$ 49,862	$ 24
Ending Balance (shares) at Dec. 31, 2022		105,263,000

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Operating Activities:
Net income	$ 83,079	$ 39,482	$ 74,983
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation	141	192	92
Amortization of intangible assets	1,098
Stock-based compensation	7,907	6,073	6,261
Deferred taxes	4,937	9,316	(32,971)
Change in accrued interest and accretion of discount on investments	17	(5)	(12)
Reduction in the carrying amount of right-of-use asset	247	292	793
Realized loss on sale of available-for-sale securities	762
Acquired research and development inventory expensed from asset acquisition	4,130
(Increase) decrease in:
Accounts receivable, net	(3,820)	(632)	4,549
Inventory	1,065	(3,219)	(2,694)
Prepaid expenses and other current assets and deposits	(807)	3,977	(3,977)
Increase (decrease) in:
Accounts payable	1,207	(1,488)	138
Accrued expenses and other liabilities	16,391	5,520	(1,209)
Operating lease liability	(307)	864	(919)
Net cash provided by (used in) operating activities	116,047	60,372	45,034
Investing Activities:
Purchases of property and equipment	(29)	(1,021)	(11)
Purchases of investments		(10,000)	(10,000)
Proceeds from maturities and sale of available-for-sale securities	19,238		5,000
Payment in connection with license agreement	(10,000)
Net cash provided by (used in) investing activities	9,209	(11,021)	(5,011)
Financing Activities:
Payment of employee withholding tax related to stock-based compensation	(230)	(153)	(56)
Proceeds from exercise of stock options	9,569	4,099	758
Repurchase of common stock	(6,907)	(12,089)
Payment of liabilities arising from asset acquisition	(738)
Net cash provided by (used in) financing activities	1,694	(8,143)	702
Net increase in cash and cash equivalents	126,950	41,208	40,725
Cash and cash equivalents – beginning of period	171,445	130,237	89,512
Cash and cash equivalents – end of period	298,395	171,445	130,237
Supplemental disclosures of cash flow information:
Cash paid for income taxes	7,667	3,000	$ 2,785
Non-cash investing and financing activities:
Operating lease liabilities arising from obtaining right-of-use assets		$ 3,309
Liabilities arising from asset acquisition	$ 27,699

Organization and Description of

Organization and Description of Business	12 Months Ended
Organization and Description of Business	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	1. Organization and Description of Business. Catalyst Pharmaceuticals, Inc. and subsidiary (collectively, the “Company”) is a commercial-stage biopharmaceutical company focused on in-licensing, best-in-class Catalyst’s New Drug Application for FIRDAPSE ® ® ® ® ® Since inception, the Company has devoted substantially all its efforts to business planning, research and development, recruiting management and technical staff, acquiring operating assets, raising capital, and selling its product. The Company incurred operating losses in each period from inception and started reporting operating income during the year ended December 31, 2019. The Company has been able to fund its cash needs to date through offerings of its securities and from revenues from sales of its product. See Note 15 (Stockholders’ Equity). Capital Resources While there can be no assurance, based on currently available information, the Company estimates that it has sufficient resources to support its operations for at least the next 12 months from the issuance date of this report. The Company may raise funds in the future through public or private equity offerings, debt financings, corporate collaborations, governmental research grants or other means. The Company may also seek to raise new capital to fund additional drug development efforts, even if it has sufficient funds for its planned operations. Any sale by the Company of additional equity or convertible debt securities could result in dilution to the Company’s current stockholders. There can be no assurance that any required additional funding will be available to the Company at all or available on terms acceptable to the Company. Further, to the extent that the Company raises additional funds through collaborative arrangements, it may be necessary to relinquish some rights to the Company’s drug candidates or grant sublicenses on terms that are not favorable to the Company. If the Company is not able to secure additional funding when needed, the Company may have to delay, reduce the scope of, or eliminate one or more research and development programs, which could have an adverse effect on the Company’s business. Risks and Uncertainties There are numerous aspects of the coronavirus (COVID-19)

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	12 Months Ended
Basis of Presentation and Significant Accounting Policies	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	2. Basis of Presentation and Significant Accounting Policies. a. PRINCIPLES OF CONSOLIDATION. b. USE OF ESTIMATES. c. CASH AND CASH EQUIVALENTS. d. INVESTMENTS. The U.S. Treasuries held at December 31, 2022 are classified as available-for-sale non-current non-current The Company records available-for-sale available-for-sale available-for-sale available-for-sale Note e. ACCOUNTS RECEIVABLE, NET. f. INVENTORY work-in-process first-in, ® ® Products that have been approved by the FDA or other regulatory authorities, such as FIRDAPSE ® ® The Company evaluates for potential excess inventory by analyzing current and future product demand relative to the remaining product shelf life. The Company builds demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market g. PREPAID EXPENSES AND OTHER CURRENT ASSETS. pre-clinical h. PROPERTY AND EQUIPMENT, NET. three five five i BUSINESS COMBINATIONS AND ASSET ACQUISITIONS Refer to Notes 12 (Commitments and Contingencies) and 13 (Agreements) for further discussion on the Company’s exclusive license agreement with Jacobus Pharmaceutical Company, Inc (Jacobus), for the rights to develop and commercialize RUZURGI ® j. INTANGIBLE The Company reviews intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are deemed not recoverable, the Company would estimate the fair value of the assets and record an impairment loss. k. FAIR VALUE OF FINANCIAL INSTRUMENTS. l. FAIR VALUE MEASUREMENTS. Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level 3 inputs are unobservable inputs for the asset or liability, which are typically based on an entity’s own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. Fair Value Measurements at Reporting Date Using (in thousands) Balances as of December 31, 2022 Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Cash and cash equivalents: Money market funds $ 168,853 $ 168,853 $ — $ — U.S. Treasuries $ 105,442 $ 105,442 $ — $ — Balances as of December 31, 2021 Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Cash and cash equivalents: Money market funds $ 10,990 $ 10,990 $ — $ — U.S. Treasuries $ 140,995 $ 140,995 $ — $ — Short-term investments: Short-term bond funds $ 19,821 $ 19,821 $ — $ — m OPERATING LEASES. right-of-use non-lease n SHARE REPURCHASES. The Company accounts for share repurchases by charging the excess of the repurchase price over the repurchased common stock’s par value entirely to retained earnings (accumulated deficit). All repurchased shares are retired and become authorized but unissued shares. The o REVENUE RECOGNITION. Product Revenues: The Company recognizes revenue when its customer obtains title of the promised goods, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for these goods. Subsequent to receiving FDA approval, the Company entered into an arrangement with one distributor (the “Customer”), which is the exclusive distributor of FIRDAPSE ® ® ® To determine revenue recognition for arrangements that are within the scope of Accounting Standards Codification (“ASC”) Topic 606 – Revenue from Contracts with Customers (“Topic 606”), the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company assesses the goods or services promised within each contract and determines those that are performance obligations by assessing whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. For a complete discussion of accounting for product revenue, see Product Revenue, Net below. The Company also may generate revenues from payments received under collaborative and license agreements. Collaborative and license agreement payments may include nonrefundable fees at the inception of the agreements, contingent payments for specific achievements designated in the agreements, and/or net profit-sharing payments on sales of products resulting from the collaborative and license arrangements. For a complete discussion of accounting for collaborative and licensing arrangements, see Revenues from Collaboration and Licensing Arrangements below. Product Revenue, Net: ® ® The Company recognizes revenue on product sales when the Customer obtains control of the Company’s product, which occurs at a point in time (upon delivery or upon dispense to patient). Product revenue is recorded net of applicable reserves for variable consideration, including discounts and allowances. The Company’s payment terms range between 15 and 30 days. Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales. If taxes should be collected from the Customer relating to product sales and remitted to governmental authorities, they will be excluded from revenue. The Company expenses incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that the Company would have recognized is one year or less. However, no such costs were incurred during the years ended December 31, 2022, 2021 and 2020. During the years ended December 31, 2022, 2021 and 2020, principally all of the Company’s sales of FIRDAPSE ® Reserves for Variable Consideration: These estimates take into consideration a range of possible outcomes which are probability-weighted in accordance with the expected value method in Topic 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted Customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the respective underlying contracts. The amount of variable consideration which is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. The Company’s analyses also contemplates application of the constraint in accordance with the guidance, under which it determined a material reversal of revenue would not occur in a future period for the estimates detailed below as of December 31, 2022 and, therefore, the transaction price was not reduced further during the years ended December 31, 2022, 2021 and 2020. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known. Trade Discounts and Allowances: ® Prompt Payment Discounts: Funded Co-pay co-pay co-pay ® Product Returns: Provider Chargebacks and Discounts: Government Rebates: The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period. Bridge and Patient Assistance Programs: ® pre-established ® ® ® ® Revenues from Collaboration and Licensing Arrangements: The Company analyzes license and collaboration arrangements pursuant to FASB ASC Topic 808, Collaborative Arrangement Guidance and Consideration, (“Topic 808”) to assess whether such arrangements, or transactions between arrangement participants, involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities or are more akin to a vendor-customer relationship. In making this evaluation, the Company considers whether the activities of the collaboration are considered to be distinct and deemed to be within the scope of the collaborative arrangement guidance or if they are more reflective of a vendor-customer relationship and, therefore, within the scope of Topic 606. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For elements of collaboration arrangements that are not accounted for pursuant to guidance in Topic 606, an appropriate recognition method is determined and applied consistently, generally by analogy to the revenue from contracts with customers guidance. The Company evaluates the performance obligations promised in the contract that are based on goods and services that will be transferred to the customer and determines whether those obligations are both (i) capable of being distinct and (ii) distinct in the context of the contract. Goods or services that meet these criteria are considered distinct performance obligations. The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. The agreements provide for milestone payments upon achievement of development and regulatory events. The Company accounts for milestone payments as variable consideration in accordance with Topic 606. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of potential transaction price and the likelihood that the transaction price will be received. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Arrangements that include rights to additional goods or services that are exercisable at a customer’s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and, if so, these options are considered performance obligations. After contract inception, the transaction price is reassessed at every period end and updated for changes such as resolution of uncertain events. Any change in the overall transaction price is allocated to the performance obligations based on the same methodology used at contract inception. The Company recognizes sales-based royalties or net profit-sharing when the later of (a) the subsequent sale occurs, or (b) the performance obligation to which the sales-based royalty or net profit-sharing has been allocated has been satisfied. Payments to and from the collaborator are presented in the statement of operations based on the nature of the Company’s business operations, the nature of the arrangement, including the contractual terms, and the nature of the payments. Refer p RESEARCH AND DEVELOPMENT. q ADVERTISING EXPENSE. ® r STOCK-BASED COMPENSATION. one s CONCENTRATION OF RISK. The Company sells its product in the United States through an exclusive distributor (its Customer) to SPs. Therefore, its distributor and SPs account for principally all of its trade receivables and net product revenues. The creditworthiness of its Customer is continuously monitored, and the Company has internal policies regarding customer credit limits. The Company estimates an allowance for expected credit loss primarily based on the credit worthiness of its Customer, historical payment patterns, aging of receivable balances and general economic conditions. As of December 31, 2022, the Company had a single product, which made it difficult to evaluate its current business, predict its future prospects, and forecast financial performance and growth. The Company had invested a significant portion of its efforts and financial resources in the development and commercialization of the lead product, FIRDAPSE ® ® ® The Company relies exclusively on third parties to formulate and manufacture FIRDAPSE ® ® ® commercial t ROYALTIES. ® u INCOME TAXES. The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not tax 8 v COMPREHENSIVE INCOME. available-for-sale w NET INCOME PER COMMON SHARE. Diluted net income per common share is computed by dividing net income by the weighted average number of common shares outstanding, increased by the assumed conversion of other potentially dilutive securities during the period. The following table reconciles basic and diluted weighted average common shares: For the Years Ended December 31, 2022 2021 2020 Basic weighted average common shares outstanding 103,374,606 103,379,349 103,512,913 Effect of dilutive securities 8,001,025 4,416,236 2,729,360 Diluted weighted average common shares outstanding 111,375,631 107,795,585 106,242,273 Outstanding 2 x SEGMENT INFORMATION. y RECLASSIFICATIONS. at z RECENTLY ISSUED ACCOUNTING STANDARDS.

Investments

Investments	12 Months Ended
Investments	Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Investments	3. Investments. Available- for Estimated Fair Value Gross Unrealized Gains Gross Unrealized Losses Amortized Cost At December 31, 2022: U.S. Treasuries - Cash equivalents $ 105,442 $ 32 $ — $ 105,410 Total $ 105,442 $ 32 $ — $ 105,410 At December 31, 2021: U.S. Treasuries - Cash equivalents $ 140,995 $ 2 $ — $ 140,993 Short-term bond funds 19,821 — (196 ) 20,017 Total $ 160,816 $ 2 $ (196 ) $ 161,010 There available-for-sale available-for-sale The estimated fair values of available-for-sale 31 2022 Due in one year or less $ 105,442

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	12 Months Ended
Accumulated Other Comprehensive Income (Loss)	Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Accumulated Other Comprehensive Income (Loss)	4. Accumulated Other Comprehensive Income (Loss). The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax from unrealized gains (losses) on available-for-sale comprehensive The amount reclassified out of accumulated other comprehensive income (loss), net of tax and into net income during the year ended December 31, 2022, was solely due to a realized loss from sale of available-for-sale Total Accumulated Other Comprehensive Income (Loss) Balance at December 31, 2021 $ (148 ) Other comprehensive gain (loss) before reclassifications (590 ) Amount reclassified from accumulated other comprehensive income 762 Net current period other comprehensive gain (loss) 172 Balance at December 31, 2022 $ 24

Inventory

Inventory	12 Months Ended
Inventory	Dec. 31, 2022
Inventory Disclosure [Abstract]
Inventory	5. Inventory. Inventory December 31, 2022 December 31, 2021 Raw materials $ — $ 1,769 Work-in-process 5,543 5,172 Finished goods 1,262 929 Total inventory $ 6,805 $ 7,870

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
Prepaid Expenses and Other Current Assets	Dec. 31, 2022
Text Block [Abstract]
Prepaid Expenses and Other Current Assets	6. Prepaid Prepaid expenses and other current assets consist of the following (in thousands): December 31, 2022 December 31, 2021 Prepaid manufacturing costs $ 1,147 $ 307 Prepaid tax 44 564 Prepaid insurance 1,224 1,213 Prepaid subscriptions fees 1,202 909 Prepaid research fees 178 452 Prepaid commercialization expenses 198 195 Due from collaborative and licensing arrangements 354 105 Prepaid conference and travel expenses 234 279 Other 577 327 Total prepaid expenses and other current assets $ 5,158 $ 4,351

Operating Leases

Operating Leases	12 Months Ended
Operating Leases	Dec. 31, 2022
Operating Lease, Lease Income [Abstract]
Operating Leases	7. Operating Leases. The Company has an operating lease agreement for its corporate office. The lease includes an option to extend the lease for up to 5 years and options to terminate the lease within 6 and 7.6 years. There are no obligations under finance leases. The Company entered into an agreement in May 2020 that amended its lease for its office facilities. Under the amended lease, the Company’s leased space increased from The components of lease expense were as follows (in thousands): For the Years Ended December 31, 2022 2021 Operating lease cost $ 431 $ 379 Supplemental cash flow information related to lease was as follows (in thousands): For the Years Ended December 31, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows $ 492 $ 109 Right-of-use Operating lease $ 89 $ 80 Supplemental balance sheet information related to lease was as follows (in thousands): December 31, 2022 December 31, 2021 Operating lease right-of-use $ 2,770 $ 3,017 Other current l $ 337 $ 308 Operating lease liabilities, net of current portion 3,557 3,894 Total operating lease liabilities $ 3,894 $ 4,202 As of December 31, 2022 and December 31, 2021, the weighted average remaining lease term was 8.3 years and 9.3 years, respectively. The weighted average discount rate used to determine the operating lease liabilities was 4.51% as of December 31, 2022 and December 31, 2021. Remaining payments of lease liabilities as of December 31, 2022 were as follows (in thousands): 2023 $ 506 2024 522 2025 537 2026 553 2027 570 Thereafter 2,027 Total lease payments 4,715 Less: imputed interest (821 ) Total $ 3,894 Rent expense was $0.4 million, $0.4 million and $0.3 million for the

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
Property and Equipment, Net	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	8. Property and Equipment, Net. Property and equipment, net consists of the following (in thousands): December 31, 2022 December 31, 2021 Computer equipment $ 51 $ 51 Furniture and equipment 222 203 Leasehold improvements 980 980 Less: Accumulated depreciation (406 ) (275 ) Total property and equipment, net $ 847 $ 959

License and Acquired Intangible

License and Acquired Intangibles, Net	12 Months Ended
License and Acquired Intangibles, Net	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
License and Acquired Intangibles, Net	9. License and Acquired Intangibles, Net. The following table presents the Company’s intangible assets at December 31, 2022 (in thousands): Gross Carrying Value Accumulated Amortization Net Carrying Value Intangible assets: License and acquired intangibles for RUZURGI ® $ 33,569 $ 1,098 $ 32,471 Total $ 33,569 $ 1,098 $ 32,471 The Company amortizes its definite-lived intangible assets using the straight-line method, which is considered the best estimate of economic benefit, over its estimated useful life of approximately 14.5 years. Amortization of these assets during each of the next five years is estimated to be approximately $2.3 million per year. The Company recorded approximately $1.1 million in amortization expense related to the licensed and acquired intangibles for RUZURGI ® If all or a portion of the intangible assets are deemed not recoverable, the Company would estimate the fair value of the assets and record an impairment loss. There were no impairment charges recognized on definite-lived intangibles for the year ended December 31, 2022. There were no definite-lived intangible assets at December 31, 2021.

Accrued Expenses and Other Liab

Accrued Expenses and Other Liabilities	12 Months Ended
Accrued Expenses and Other Liabilities	Dec. 31, 2022
Payables and Accruals [Abstract]
Accrued Expenses and Other Liabilities	10. Accrued Expenses and Other Liabilities. Accrued 2022 2021 Accrued preclinical and clinical trial expenses $ 479 $ 659 Accrued professional fees 1,619 2,391 Accrued compensation and benefits 5,132 4,035 Accrued license fees 20,444 12,819 Accrued purchases 154 2,045 Operating lease liability 337 308 Accrued variable consideration 3,381 1,716 Accrued income tax 8,702 79 Due to licensor 13,127 — Other 238 243 Current accrued expenses and other liabilities 53,613 24,295 Lease liability – non-current 3,557 3,894 Due to licensor – non-current 14,064 — Non-current 17,621 3,894 Total accrued expenses and other liabilities $ 71,234 $ 28,189

Collaborative and Licensing Arr

Collaborative and Licensing Arrangements	12 Months Ended
Collaborative and Licensing Arrangements	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborative and Licensing Arrangements	11. Collaborative and Licensing Arrangements. Endo In December 2018, the Company entered into a collaboration and license agreement (Collaboration) with Endo, for the further development and commercialization of generic Sabril ® ® Under the terms of the Collaboration, the Company has received an up-front mid-double ® The Company evaluated the license agreement with Endo to determine whether it is a collaborative arrangement for purposes of Topic 808. As the Company shares in the significant risks and rewards, the Company has concluded that this is a collaborative arrangement. As developing a final finished dosage form of a generic product in exchange for consideration is not an output of the Company’s ongoing activities, Endo does not represent a contract with a customer. However, Topic 808 does not provide guidance on the recognition of consideration exchanged or accounting for the obligations that may arise between the parties. The Company concluded that ASC Topic 730, Research and Development The collaborative agreement included a nonrefundable upfront license fee that was recognized upon receipt following execution of the collaborative arrangement for vigabatrin tablets. The collaborative agreement provides for a $2.0 million milestone payment on the commercial launch of the product by Endo/Par. As of December 31, 2022, 2021 and 2020, no milestone payments have been earned. There were no revenues from this collaborative arrangement for the years ended December 31, 2022, 2021 or 2020. Total expenses incurred, net, in connection with the collaborative agreement for the years ended December 31, 2022, 2021 and 2020 were approximately $0, $45,000 and $4,200, respectively. These expenses have been included in research and development expenses in the accompanying consolidated statements of operations and comprehensive income. KYE Pharmaceuticals Inc. In August 2020, the Company entered into a collaboration and license agreement with KYE Pharmaceuticals Inc. (KYE), for the commercialization of FIRDAPSE ® Under the agreement, Catalyst granted KYE an exclusive license to commercialize and market FIRDAPSE ® ® Under the terms of the agreement, the Company will receive an up-front ® mid-double-digit ® This agreement is in form identified as a collaborative agreement and the Company has concluded for accounting purposes that it also represents a contract with a customer. This is because the Company grants to KYE a license and provides supply of FIRDAPSE ® The collaborative agreement included a nonrefundable upfront license fee that was recognized upon transfer of the license based on a determination that the right is provided as the intellectual property exists at the point in time in which the license is granted. Under the arrangement, the Company will receive profit-sharing reports within nine days after quarter end from KYE. Revenue from sales of FIRDAPSE ® Revenues from the arrangement with KYE for the years ended December 31, 2022, 2021 and 2020 were not material. Revenue is included in product revenue, net and license and other revenue in the accompanying consolidated statements of operations and comprehensive income. Expenses incurred, net have been included in selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive income. DyDo Pharma, Inc. On June 28, 2021, the Company entered into a license agreement with DyDo Pharma, Inc. (DyDo), for the development and commercialization of FIRDAPSE ® Under the agreement, DyDo has joint rights to develop FIRDAPSE ® Under the terms of the agreement, the Company has earned an up-front ® The Company has concluded that this license agreement will be accounted for pursuant to Topic 606. The agreement included a nonrefundable upfront license fee that was recognized upon the effective date of the agreement as the intellectual property exists at the point in time in which the right to the license is granted. The Company determined the granting of the right to the license is distinct from the supply of FIRDAPSE ® The agreement includes milestones that are considered a sales-based royalty in which the license is deemed to be the predominant item to which these milestones relate. Revenue will be recognized when the later of (a) the subsequent sale occurs, or (b) the performance obligation to which the sales-based royalty has been allocated has been satisfied. Additionally, the agreement includes regulatory milestone payments which represent variable consideration, and due to uncertainty are fully constrained and only recognized when the uncertainty is subsequently resolved. For clinical and commercial supply of the product, the Company will recognize revenue when the Customer obtains control of the Company’s product, which will occur at a point in time which is generally at time of shipment. There was $0.5 million in revenue from the arrangement with DyDo for the year ended December 31, 2022, which is included in product revenue, net in the accompanying consolidated statements of operations and comprehensive income. Revenues from the arrangement with DyDo for the year ended December 31, 2021 w ere million, which primarily consisted of a $2.7 million nonrefundable upfront license fee, which is included in licensing and other revenue in the accompanying consolidated statements of operations and comprehensive income. As of December 31, 2022

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	12. Commitments and Contingencies. In May 2019, the FDA approved a New Drug Application (NDA) for RUZURGI ® (3,4-DAP), ® ® On July 30, 2020, the Magistrate Judge considering this lawsuit filed a Report and Recommendation in which she recommended to the District Judge handling the case that she grant the FDA’s and Jacobus’ motions for summary judgment and deny the Company’s motion for summary judgment. On September 29, 2020, the District Judge adopted the Report and Recommendation of the Magistrate Judge, granted the FDA’s and Jacobus’ motions for summary judgment, and dismissed the Company’s case. The Company appealed the District Court’s decision to the U.S. Court of Appeals for the 11 th On September 30, 2021, a three-judge panel of 11 th ® th th th th th ® 7-year ® On July 11, 2022, the Company settled certain of its disputes with Jacobus. In connection with the settlement, the Company licensed the rights to develop and commercialize RUZURGI ® ® ® ® know-how ® ® ® non-competition In connection with the settlement with Jacobus, the Company agreed to pay the following consideration to Jacobus: • $30 million of cash, of which $10 million was paid at the closing of the settlement on July 11, 2022 and the balance of which will be paid over the next two years, on the first and second anniversary of closing; • An annual royalty on our net sales (as defined in the License and Asset Purchase Agreement between Catalyst and Jacobus) of amifampridine products in the United States equal to: (a) for calendar years 2022 through 2025, 1.5% (with a minimum annual royalty of $3.0 million per year), and (b) for calendar years 2026 through the expiration of the last to expire of Catalyst’s FIRDAPSE ® • If Catalyst were to receive a priority review voucher for FIRDAPSE ® ® Royalties will be trued up at the end of the year to the extent that royalties on net sales are below the minimum royalty. The Company’s New Drug Submission filing for FIRDAPSE ® ® ® ® ® ® On June 3, 2021, the Company announced a positive decision in this proceeding that quashed the NOC previously issued for RUZURGI ® ® ® re-issued ® On March 11, 2022, the Company announced that the Company had received a favorable decision from the Canadian court setting aside, for the second time, the decision of Health Canada approving RUZURGI ® ® ® ® ® Additionally, from time to time the Company may become involved in legal proceedings arising in the ordinary course of business. Except as set forth above, the Company believes that there is no other litigation pending at this time that could have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition, or cash flows.

Agreements

Agreements	12 Months Ended
Agreements	Dec. 31, 2022
Text Block [Abstract]
Agreements	13. Agreements. a. LICENSE AGREEMENT FOR FIRDAPSE ® ® ® ® On May 29, 2019, the Company and BioMarin entered into an amendment to the Company’s license agreement for FIRDAPSE ® ® In January 2020, the Company was advised that BioMarin has transferred certain rights under the license agreement to SERB S.A. b. LICENSE AGREEMENT FOR RUZURGI ® ® Pursuant to the terms of the license agreement, the Company paid Jacobus a $10 million up-front ® million, provided that such minimum annual royalty payment shall be prorated in the first calendar year of the agreement. As these minimum payments are both probable and estimable, they are included in the purchase price of the agreement and any royalties in excess of this amount will be charged to cost of sales as revenue from product sales is recognized. A minimum royalty payment exists annually for calendar years from 2026 through the expiration of the royalty term (which ends when there is no valid claim under the Company’s FIRDAPSE ® of $ million unless a competing product or generic version of FIRDAPSE ® is being marketed or sold in the United States. As these minimum payments are not probable and estimable, they will be charged to cost of sales as revenue from product sales is recognized. Royalties over the minimum, if any, will be paid based on the agreement terms on a quarterly basis. Assets acquired as part of the license agreement include among other intellectual property rights, Jacobus’ U.S. patents related to RUZURGI ® ® ® ® know-how ® Additionally, the Company also purchased from Jacobus approximately $4.1 million of RUZURGI ® Under business combination guidance, the screen test states that if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets, the set is not considered a business and is accounted for as an asset acquisition. The Company has determined that the screen test was not met. However, the Company determined that the acquisition did not meet the definition of a business under ASC 805, Business Combination. The Company believes that the licensing agreement and other assets acquired from Jacobus are similar and considered them all to be intangible assets with the exception of the inventory acquired. As the screen test was not met, further determination was required to determine that the Company had not acquired inputs and processes that have the ability to create outputs, which would meet the requirements of a business, and therefore, determined that this was an asset acquisition. The Company accounted for the Jacobus license agreement as an asset acquisition under ASC 805-50, which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, which includes consideration given. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values. The total purchase price was allocated to the acquired assets based on their relative fair values, as follows (in thousands): License and acquired intangibles $ 33,569 Acquired research and development inventory expensed from asset acquisition 4,130 Total purchase price $ 37,699 The straight-line method is used to amortize the license and acquired intangibles, as disclosed in Note 9 (License and Acquired Intangibles, Net). c. AGREEMENTS FOR DRUG MANUFACTURING, DEVELOPMENT, PRECLINICAL AND CLINICAL STUDIES.

Income Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	14. Income Taxes. The Company is subject to income taxes in the U.S. federal jurisdiction and various states jurisdictions. The income tax expense (benefit) for the years ended December 31, 2022, 2021, and 2020 consists of (in thousands): 2022 2021 2020 Current - Federal $ 12,858 $ 2,455 $ — Current - State 3,877 1,414 (122 ) Deferred - Federal 4,739 8,620 (29,378 ) Deferred - State 166 696 (3,593 ) $ 21,640 $ 13,185 $ (33,093 ) The 21 follows: 2022 2021 2020 Statutory rate 21.0 % 21.0 % 21.0 % State tax 3.1 % 3.4 % 2.2 % Valuation allowance — — (99.4 )% Executive compensation limitation 3.6 % 1.1 % — Tax credit (1.9 )% (0.6 )% (2.4 )% Stock compensation windfall (5.6 )% (0.6 )% — Other 0.5 % 0.7 % (0.4 )% 20.7 % 25.0 % (79.0 )% Deferred tax assets and liabilities reflect the net tax effects of net operating loss and tax credit carryovers and the temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets/(liabilities) as of December 31, 2022 and 2021 are as follows (in thousands): 2022 2021 Deferred tax assets: Net operating loss $ — $ 1,218 Start-up 9,771 10,403 Tax credits — 8,516 Deferred compensation 4,706 3,959 Inventory 296 163 Operating lease liability 953 1,003 Capitalized research 4,255 — Other 96 — Total deferred tax assets 20,077 25,262 Deferred tax liabilities: Prepaid expenses (481 ) (455 ) Right-of (860 ) (936 ) Other — (174 ) Total deferred tax liabilities (1,341 ) (1,565 ) Deferred tax assets, net $ 18,736 $ 23,697 The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. As of December 3 1 are realizable. At December 31, 2022 and 2021, respectively, the Company had state net operating loss carryforwards of approximately $ 0 million and $ 28 million, respectively, available to reduce future Florida taxable income. During 2020, the Company completed an analysis to determine whether, as a result of prior ownership changes, the utilization of certain net operating loss and orphan drug tax credit carryforwards would be subject to annual limitations under Sections 382 and 383 of the Internal Revenue Code and similar state provisions. In this analysis, the Company determined that the total net operating loss and orphan drug tax credit carryforwards were fully utilizable. Beginning in 2010, the Company has received several orphan drug designations by the FDA for products currently under development. The orphan drug designations allow the Company to claim increased federal tax credits for certain research and development activities. An immaterial amount of interest and penalties were accrued through December 31, 2022. While an immaterial amount of interest and penalties were accrued through December 31, 2021. The Company’s policy is to recognize any related interest or penalties in income tax expense. The Company is not currently under income tax examinations by any tax authorities.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
Stockholders' Equity	Dec. 31, 2022
Equity [Abstract]
Stockholders' Equity	15. Stockholders’ Equity. Preferred Stock The Company has 5,000,000 shares of authorized preferred stock, $0.001 par value per share, at December 31, 2022 and 2021. No shares of preferred stock were outstanding at December 31, 2022 and 2021. Common Stock The Company has 200,000,000 shares of authorized common stock, par value $0.001 per share. At December 31, 2022 and 2021, 105,263,031 and 102,992,913 shares, respectively, of common stock were issued and outstanding. Each holder of common stock is entitled to one vote of each share of common stock held of record on all matters on which stockholders generally are entitled to vote. Share Repurchases In March 2021, the Company’s Board of Directors approved a share repurchase program that authorizes the repurchase of up to $40 million of the Company’s common stock, pursuant to a repurchase plan under Rule 10b-18 2020 Shelf Registration Statement On July 23, 2020, the Company filed a shelf registration statement with the SEC to sell up to $200 million of common stock, preferred stock, warrants to purchase common stock, debt securities and units consisting of one or more of such securities (the “2020 Shelf Registration Statement”). The 2020 Shelf Registration Statement (file no. 333-240052) Stockholder Rights Plan On September 20, 2011, the Board of Directors approved the Company’s adoption of a Stockholder Rights Plan. Under the Stockholders’ Rights Plan, a dividend of one preferred share purchase right (a Right) was declared for each share of common stock of the Company that was outstanding on October 7, 2011. Each Right entitled the holder to purchase from the Company one one-hundredth The Rights traded automatically with the common stock and were not exercisable until a person or group had become an “acquiring person” by acquiring 17.5% or more of the Company’s outstanding common stock, or a person or group commenced, or publicly announced a tender offer that would result in such a person or group owning 17.5% or more of the Company’s outstanding common stock. Upon announcement that any person or group had become an acquiring person, each Right would entitle all rightholders (other than the acquiring person) to purchase, for the exercise price of $7.80, a number of shares of the Company’s common stock having a market value equal to twice the exercise price. Rightholders would also be entitled to purchase common stock of the acquiring person having a value of twice the exercise price if, after a person had become an acquiring person, the Company were to enter into certain mergers or other transactions. If any person becomes an acquiring person, the Board of Directors may, at its option and subject to certain limitations, exchange one share of common stock for each Right. The Rights had certain anti-takeover effects, in that they would cause substantial dilution to a person or group that attempts to acquire a significant interest in the Company on terms not approved by the Board of Directors. In the event that the Board of Directors determines a transaction to be in the best interests of the Company and its stockholders, the Board of Directors may redeem the Rights for $0.001 per share at any time prior to a person or group becoming an acquiring person. On September 19, 2016, the Board of Directors unanimously approved, and on the same date the Company entered into Amendment No. 1 to the Stockholders Rights Plan (the “Amendment”). Under the terms of the Amendment, the outside expiration date of the rights plan was extended to September 20, 2019. Additionally, as part of the Amendment, the Board adopted a Certificate of Designation, Preferences and Rights of Series A Junior Participating Preferred Stock of the Company to increase the number of shares of Series A Junior Participating Preferred Stock of the Company available for issuance under the Rights Plan from 500,000 shares to 1.5 million shares. On On November 12, 2021, the Board of Directors terminated the Rights Plan. Despite the termination of the Rights Plan, the Board of Directors reserves the right to take all necessary actions it deems appropriate in the future to protect the interests of all of the Company’s stockholders.

Stock Compensation

Stock Compensation	12 Months Ended
Stock Compensation	Dec. 31, 2022
Share-based Payment Arrangement [Abstract]
Stock Compensation	16. Stock Compensation. For the years ended December 31, 2022, 2021 and 2020, the Company recorded stock-based compensation expense as follows (in thousands): 2022 2021 2020 Research and development $ 1,729 $ 1,611 $ 1,585 Selling, general and administrative 6,178 4,462 4,676 Total stock-based compensation $ 7,907 $ 6,073 $ 6,261 The Company may issue stock options, restricted stock, stock appreciation rights and restricted stock units (collectively, the “Awards”) to employees, directors, and consultants of the Company under the 2014 and 2018 Stock Incentive Plans (the 2014 Plan and the 2018 Plan or collectively, the Plans). At December 31, 2022, no shares remain available for future issuance under the 2014 Plan. Under the 2018 Plan, 15,000,000 shares are reserved for issuance and as of December 31, 2022, 2,691,791 shares remain available for future issuance. Stock Options The Company has granted stock options to employees, officers, directors, and consultants generally at exercise prices equal to the market price of the common stock at grant date. Option awards generally vest over a period of 1 to 3 years of continuous service and have contractual terms of 7 years. Certain awards provide for accelerated vesting if there is a change in control. The Company issues new shares as shares are required to be delivered upon exercise of outstanding stock options. During the years ended December 31, 2022, 2021 and 2020, options to purchase 3,172,342, 1,328,936 and 281,762 shares, respectively, of the Company’s common stock were exercised with gross proceeds to the Company of approximately $9.6 million, $4.1 million and $0.8 million, respectively. During the years ended December 31, 2022, 2021 and 2020, no options to purchase shares of the Company’s common stock were exercised on a “cashless” basis. During the years ended December 31, 2022, 2021 and 2020 the Company recorded non-cash During the years ended December 31, 2022, 2021 and 2020, the Company granted seven-year options to purchase an aggregate of 1,386,500, 2,330,000 and 2,715,000 shares, respectively, of the Company’s common stock to certain of the Company’s officers, employees, directors, and consultants. Stock option activity under the Company’s Plans for the year ended December 31, 2022 is summarized as follows: Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (in thousands) Outstanding at beginning of year 14,207,728 $ 3.55 Granted 1,386,500 14.82 Exercised or released (3,172,342 ) 3.02 Forfeited or cancelled (112,778 ) 5.73 Expired — — Outstanding at end of year 12,309,108 $ 4.93 3.85 $ 168,222 Exercisable at end of year 8,534,665 $ 3.29 3.00 $ 130,686 Other information pertaining to stock option activity during the years ended December 31, 2022, 2021 and 2020 was as follows: 2022 2021 2020 Weighted–average fair value of granted stock options $ 8.52 $ 3.24 $ 2.33 Total fair value of vested stock options (in thousands) $ 6,096 $ 6,421 $ 5,312 Total intrinsic value of exercised stock options (in thousands) $ 31,881 $ 3,623 $ 325 As of December 31, 2022, there was approximately $16.7 million of unrecognized compensation expense related to non-vested The Company utilizes the Black-Scholes option-pricing model to determine the fair value of stock options on the date of grant. This model derives the fair value of stock options based on certain assumptions related to the expected stock price volatility, expected option life, risk-free interest rate and dividend yield. Expected volatility is based on reviews of historical volatility of the Company’s common stock. The Company estimates the expected option life for options granted to employees and directors based upon the simplified method. Under this method, the expected life is presumed to be the mid-point Assumptions used during the years were as follows: 2022 2021 2020 Risk free interest rate 1.27% to 4.07% 0.34% to 1.18% 0.24% to 1.64% Expected term 4.5 years 4.5 – 4.8 years 4.5 years Expected volatility 68.4% to 69.5% 68.6% to 72.8% 80.5% to 83.7% Expected dividend yield — — — Expected forfeiture rate — — — Restricted Stock Units Under the 2018 Plan, participants may be granted restricted stock units, each of which represents a conditional right to receive shares of common stock in the future. The restricted stock units granted under this plan generally vest ratably over a three-year period. Upon vesting, the restricted stock units will convert into an equivalent number of shares of common stock. The amount of expense relating to the restricted stock units is based on the closing market price of the Company’s common stock on the date of grant and is amortized on a straight-line basis over the requisite service period. Restricted stock unit activity for the year ended December 31, 2022 was as follows; Number of Restricted Stock Units Weighted Average Grant Date Fair Value Nonvested balance at beginning of year 122,839 $ 4.65 Granted 742,500 11.55 Vested (112,839 ) 4.65 Forfeited — — Nonvested balance at end of year 752,500 $ 11.46 During the year ended December 31, 2022, 2021 and 2020, the Company recorded non-cash

Benefit Plan

Benefit Plan	12 Months Ended
Benefit Plan	Dec. 31, 2022
Retirement Benefits [Abstract]
Benefit Plan	17. Benefit Plan. The Company maintains an employee savings plan pursuant to Section 401(k) of the Internal Revenue Code covering all eligible employees. Subject to certain dollar limits, eligible employees may contribute up to 15% of their pre-tax million each year.

Subsequent Events

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	18. Subsequent Events. On January 24, 2023, the Company acquired the U.S. Rights for FYCOMPA ® Under the terms of the purchase agreement, the Company made an upfront cash payment of $160 million plus $1.6 million for reimbursement of certain prepayments. Eisai is also eligible to receive a contingent payment of $25 million if certain regulatory milestones are met and tiered royalty payments based on certain annual net sales milestones. Concurrently with the acquisition, the parties entered into two related agreements: (i) a short-term Transition Services Agreement for commercial and manufacturing services and (ii) a long-term Supply Agreement for the manufacturing of FYCOMPA ® ® Given that the acquisition was recently closed, the Company’s analysis of the accounting for the transaction is in process and is incomplete as of the filing date of this report.

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
PRINCIPLES OF CONSOLIDATION	a. PRINCIPLES OF CONSOLIDATION.
USE OF ESTIMATES	b. USE OF ESTIMATES.
CASH AND CASH EQUIVALENTS	c. CASH AND CASH EQUIVALENTS.
INVESTMENTS	d. INVESTMENTS. The U.S. Treasuries held at December 31, 2022 are classified as available-for-sale non-current non-current The Company records available-for-sale available-for-sale available-for-sale available-for-sale Note
ACCOUNTS RECEIVABLE, NET	e. ACCOUNTS RECEIVABLE, NET.
INVENTORY	f. INVENTORY work-in-process first-in, ® ® Products that have been approved by the FDA or other regulatory authorities, such as FIRDAPSE ® ® The Company evaluates for potential excess inventory by analyzing current and future product demand relative to the remaining product shelf life. The Company builds demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market
PREPAID EXPENSES AND OTHER CURRENT ASSETS	g. PREPAID EXPENSES AND OTHER CURRENT ASSETS. pre-clinical
PROPERTY AND EQUIPMENT, NET	h. PROPERTY AND EQUIPMENT, NET. three five five
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS	i BUSINESS COMBINATIONS AND ASSET ACQUISITIONS Refer to Notes 12 (Commitments and Contingencies) and 13 (Agreements) for further discussion on the Company’s exclusive license agreement with Jacobus Pharmaceutical Company, Inc (Jacobus), for the rights to develop and commercialize RUZURGI ®
INTANGIBLE ASSETS, NET	j. INTANGIBLE The Company reviews intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are deemed not recoverable, the Company would estimate the fair value of the assets and record an impairment loss.
FAIR VALUE OF FINANCIAL INSTRUMENTS	k. FAIR VALUE OF FINANCIAL INSTRUMENTS.
FAIR VALUE MEASUREMENTS	l. FAIR VALUE MEASUREMENTS. Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level 3 inputs are unobservable inputs for the asset or liability, which are typically based on an entity’s own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. Fair Value Measurements at Reporting Date Using (in thousands) Balances as of December 31, 2022 Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Cash and cash equivalents: Money market funds $ 168,853 $ 168,853 $ — $ — U.S. Treasuries $ 105,442 $ 105,442 $ — $ — Balances as of December 31, 2021 Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Cash and cash equivalents: Money market funds $ 10,990 $ 10,990 $ — $ — U.S. Treasuries $ 140,995 $ 140,995 $ — $ — Short-term investments: Short-term bond funds $ 19,821 $ 19,821 $ — $ —
OPERATING LEASES	m OPERATING LEASES. right-of-use non-lease
SHARE REPURCHASES	n SHARE REPURCHASES. The Company accounts for share repurchases by charging the excess of the repurchase price over the repurchased common stock’s par value entirely to retained earnings (accumulated deficit). All repurchased shares are retired and become authorized but unissued shares. The
REVENUE RECOGNITION	o REVENUE RECOGNITION. Product Revenues: The Company recognizes revenue when its customer obtains title of the promised goods, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for these goods. Subsequent to receiving FDA approval, the Company entered into an arrangement with one distributor (the “Customer”), which is the exclusive distributor of FIRDAPSE ® ® ® To determine revenue recognition for arrangements that are within the scope of Accounting Standards Codification (“ASC”) Topic 606 – Revenue from Contracts with Customers (“Topic 606”), the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company assesses the goods or services promised within each contract and determines those that are performance obligations by assessing whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. For a complete discussion of accounting for product revenue, see Product Revenue, Net below. The Company also may generate revenues from payments received under collaborative and license agreements. Collaborative and license agreement payments may include nonrefundable fees at the inception of the agreements, contingent payments for specific achievements designated in the agreements, and/or net profit-sharing payments on sales of products resulting from the collaborative and license arrangements. For a complete discussion of accounting for collaborative and licensing arrangements, see Revenues from Collaboration and Licensing Arrangements below. Product Revenue, Net: ® ® The Company recognizes revenue on product sales when the Customer obtains control of the Company’s product, which occurs at a point in time (upon delivery or upon dispense to patient). Product revenue is recorded net of applicable reserves for variable consideration, including discounts and allowances. The Company’s payment terms range between 15 and 30 days. Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales. If taxes should be collected from the Customer relating to product sales and remitted to governmental authorities, they will be excluded from revenue. The Company expenses incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that the Company would have recognized is one year or less. However, no such costs were incurred during the years ended December 31, 2022, 2021 and 2020. During the years ended December 31, 2022, 2021 and 2020, principally all of the Company’s sales of FIRDAPSE ® Reserves for Variable Consideration: These estimates take into consideration a range of possible outcomes which are probability-weighted in accordance with the expected value method in Topic 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted Customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the respective underlying contracts. The amount of variable consideration which is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. The Company’s analyses also contemplates application of the constraint in accordance with the guidance, under which it determined a material reversal of revenue would not occur in a future period for the estimates detailed below as of December 31, 2022 and, therefore, the transaction price was not reduced further during the years ended December 31, 2022, 2021 and 2020. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known. Trade Discounts and Allowances: ® Prompt Payment Discounts: Funded Co-pay co-pay co-pay ® Product Returns: Provider Chargebacks and Discounts: Government Rebates: The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period. Bridge and Patient Assistance Programs: ® pre-established ® ® ® ® Revenues from Collaboration and Licensing Arrangements: The Company analyzes license and collaboration arrangements pursuant to FASB ASC Topic 808, Collaborative Arrangement Guidance and Consideration, (“Topic 808”) to assess whether such arrangements, or transactions between arrangement participants, involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities or are more akin to a vendor-customer relationship. In making this evaluation, the Company considers whether the activities of the collaboration are considered to be distinct and deemed to be within the scope of the collaborative arrangement guidance or if they are more reflective of a vendor-customer relationship and, therefore, within the scope of Topic 606. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For elements of collaboration arrangements that are not accounted for pursuant to guidance in Topic 606, an appropriate recognition method is determined and applied consistently, generally by analogy to the revenue from contracts with customers guidance. The Company evaluates the performance obligations promised in the contract that are based on goods and services that will be transferred to the customer and determines whether those obligations are both (i) capable of being distinct and (ii) distinct in the context of the contract. Goods or services that meet these criteria are considered distinct performance obligations. The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. The agreements provide for milestone payments upon achievement of development and regulatory events. The Company accounts for milestone payments as variable consideration in accordance with Topic 606. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of potential transaction price and the likelihood that the transaction price will be received. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Arrangements that include rights to additional goods or services that are exercisable at a customer’s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and, if so, these options are considered performance obligations. After contract inception, the transaction price is reassessed at every period end and updated for changes such as resolution of uncertain events. Any change in the overall transaction price is allocated to the performance obligations based on the same methodology used at contract inception. The Company recognizes sales-based royalties or net profit-sharing when the later of (a) the subsequent sale occurs, or (b) the performance obligation to which the sales-based royalty or net profit-sharing has been allocated has been satisfied. Payments to and from the collaborator are presented in the statement of operations based on the nature of the Company’s business operations, the nature of the arrangement, including the contractual terms, and the nature of the payments. Refer
RESEARCH AND DEVELOPMENT	p RESEARCH AND DEVELOPMENT.
ADVERTISING EXPENSE	q ADVERTISING EXPENSE. ®
STOCK-BASED COMPENSATION	r STOCK-BASED COMPENSATION. one
CONCENTRATION OF CREDIT RISK	s CONCENTRATION OF RISK. The Company sells its product in the United States through an exclusive distributor (its Customer) to SPs. Therefore, its distributor and SPs account for principally all of its trade receivables and net product revenues. The creditworthiness of its Customer is continuously monitored, and the Company has internal policies regarding customer credit limits. The Company estimates an allowance for expected credit loss primarily based on the credit worthiness of its Customer, historical payment patterns, aging of receivable balances and general economic conditions. As of December 31, 2022, the Company had a single product, which made it difficult to evaluate its current business, predict its future prospects, and forecast financial performance and growth. The Company had invested a significant portion of its efforts and financial resources in the development and commercialization of the lead product, FIRDAPSE ® ® ® The Company relies exclusively on third parties to formulate and manufacture FIRDAPSE ® ® ® commercial
ROYALTIES	t ROYALTIES. ®
INCOME TAXES	u INCOME TAXES. The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not tax 8
COMPREHENSIVE INCOME	v COMPREHENSIVE INCOME. available-for-sale
NET INCOME PER COMMON SHARE	w NET INCOME PER COMMON SHARE. Diluted net income per common share is computed by dividing net income by the weighted average number of common shares outstanding, increased by the assumed conversion of other potentially dilutive securities during the period. The following table reconciles basic and diluted weighted average common shares: For the Years Ended December 31, 2022 2021 2020 Basic weighted average common shares outstanding 103,374,606 103,379,349 103,512,913 Effect of dilutive securities 8,001,025 4,416,236 2,729,360 Diluted weighted average common shares outstanding 111,375,631 107,795,585 106,242,273 Outstanding 2
SEGMENT INFORMATION	x SEGMENT INFORMATION.
RECLASSIFICATIONS	y RECLASSIFICATIONS. at
RECENTLY ISSUED ACCOUNTING STANDARDS	z RECENTLY ISSUED ACCOUNTING STANDARDS.

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Fair Value Measurement Specific to Assets or Liability	Fair Value Measurements at Reporting Date Using (in thousands) Balances as of December 31, 2022 Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Cash and cash equivalents: Money market funds $ 168,853 $ 168,853 $ — $ — U.S. Treasuries $ 105,442 $ 105,442 $ — $ — Balances as of December 31, 2021 Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Cash and cash equivalents: Money market funds $ 10,990 $ 10,990 $ — $ — U.S. Treasuries $ 140,995 $ 140,995 $ — $ — Short-term investments: Short-term bond funds $ 19,821 $ 19,821 $ — $ —
Basic and Dilutive Weighted Average Common Shares	The following table reconciles basic and diluted weighted average common shares: For the Years Ended December 31, 2022 2021 2020 Basic weighted average common shares outstanding 103,374,606 103,379,349 103,512,913 Effect of dilutive securities 8,001,025 4,416,236 2,729,360 Diluted weighted average common shares outstanding 111,375,631 107,795,585 106,242,273

Investments (Tables)

Investments (Tables)	12 Months Ended
Investments (Tables)	Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Summary of Available-for-Sale Investments by Security type	Available- for Estimated Fair Value Gross Unrealized Gains Gross Unrealized Losses Amortized Cost At December 31, 2022: U.S. Treasuries - Cash equivalents $ 105,442 $ 32 $ — $ 105,410 Total $ 105,442 $ 32 $ — $ 105,410 At December 31, 2021: U.S. Treasuries - Cash equivalents $ 140,995 $ 2 $ — $ 140,993 Short-term bond funds 19,821 — (196 ) 20,017 Total $ 160,816 $ 2 $ (196 ) $ 161,010
Estimated Fair Values of Available for Sale Securities	The estimated fair values of available-for-sale 31 2022 Due in one year or less $ 105,442

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (Tables)	12 Months Ended
Accumulated Other Comprehensive Income (Loss) (Tables)	Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Summary of Reclassifications out of Accumulated Other Comprehensive Income (loss)	There were no reclassifications out of accumulated other comprehensive income (loss) during the years ended December 31, 2021 or 2020. Total Accumulated Other Comprehensive Income (Loss) Balance at December 31, 2021 $ (148 ) Other comprehensive gain (loss) before reclassifications (590 ) Amount reclassified from accumulated other comprehensive income 762 Net current period other comprehensive gain (loss) 172 Balance at December 31, 2022 $ 24

Inventory (Tables)

Inventory (Tables)	12 Months Ended
Inventory (Tables)	Dec. 31, 2022
Inventory Disclosure [Abstract]
Summary of current inventory	Inventory December 31, 2022 December 31, 2021 Raw materials $ — $ 1,769 Work-in-process 5,543 5,172 Finished goods 1,262 929 Total inventory $ 6,805 $ 7,870

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
Prepaid Expenses and Other Current Assets (Tables)	Dec. 31, 2022
Text Block [Abstract]
Prepaid expenses and other current assets	Prepaid expenses and other current assets consist of the following (in thousands): December 31, 2022 December 31, 2021 Prepaid manufacturing costs $ 1,147 $ 307 Prepaid tax 44 564 Prepaid insurance 1,224 1,213 Prepaid subscriptions fees 1,202 909 Prepaid research fees 178 452 Prepaid commercialization expenses 198 195 Due from collaborative and licensing arrangements 354 105 Prepaid conference and travel expenses 234 279 Other 577 327 Total prepaid expenses and other current assets $ 5,158 $ 4,351

Operating Leases (Tables)

Operating Leases (Tables)	12 Months Ended
Operating Leases (Tables)	Dec. 31, 2022
Disclosure of Operating Leases [Abstract]
Lease, Cost	The components of lease expense were as follows (in thousands): For the Years Ended December 31, 2022 2021 Operating lease cost $ 431 $ 379
Schedule of Supplemental Cash Flow Information Related To Lease	Supplemental cash flow information related to lease was as follows (in thousands): For the Years Ended December 31, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows $ 492 $ 109 Right-of-use Operating lease $ 89 $ 80
Schedule of Supplemental Balance Sheet related To Lease	Supplemental balance sheet information related to lease was as follows (in thousands): December 31, 2022 December 31, 2021 Operating lease right-of-use $ 2,770 $ 3,017 Other current l $ 337 $ 308 Operating lease liabilities, net of current portion 3,557 3,894 Total operating lease liabilities $ 3,894 $ 4,202
Lessee, Operating Lease, Liability, Maturity	Remaining payments of lease liabilities as of December 31, 2022 were as follows (in thousands): 2023 $ 506 2024 522 2025 537 2026 553 2027 570 Thereafter 2,027 Total lease payments 4,715 Less: imputed interest (821 ) Total $ 3,894 Rent expense was $0.4 million, $0.4 million and $0.3 million for the

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
Property and Equipment, Net (Tables)	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment, net	Property and equipment, net consists of the following (in thousands): December 31, 2022 December 31, 2021 Computer equipment $ 51 $ 51 Furniture and equipment 222 203 Leasehold improvements 980 980 Less: Accumulated depreciation (406 ) (275 ) Total property and equipment, net $ 847 $ 959

License and Acquired Intangib_2

License and Acquired Intangibles, Net (Tables)	12 Months Ended
License and Acquired Intangibles, Net (Tables)	Dec. 31, 2022
Finite-Lived Intangible Assets, Net [Abstract]
Schedule of Finite-Lived Intangible Assets	The following table presents the Company’s intangible assets at December 31, 2022 (in thousands): Gross Carrying Value Accumulated Amortization Net Carrying Value Intangible assets: License and acquired intangibles for RUZURGI ® $ 33,569 $ 1,098 $ 32,471 Total $ 33,569 $ 1,098 $ 32,471

Accrued Expenses and Other Li_2

Accrued Expenses and Other Liabilities (Tables)	12 Months Ended
Accrued Expenses and Other Liabilities (Tables)	Dec. 31, 2022
Payables and Accruals [Abstract]
Schedule of Accrued Expenses and Other Liabilities	Accrued 2022 2021 Accrued preclinical and clinical trial expenses $ 479 $ 659 Accrued professional fees 1,619 2,391 Accrued compensation and benefits 5,132 4,035 Accrued license fees 20,444 12,819 Accrued purchases 154 2,045 Operating lease liability 337 308 Accrued variable consideration 3,381 1,716 Accrued income tax 8,702 79 Due to licensor 13,127 — Other 238 243 Current accrued expenses and other liabilities 53,613 24,295 Lease liability – non-current 3,557 3,894 Due to licensor – non-current 14,064 — Non-current 17,621 3,894 Total accrued expenses and other liabilities $ 71,234 $ 28,189

Agreements (Tables)

Agreements (Tables)	12 Months Ended
Agreements (Tables)	Dec. 31, 2022
Text Block [Abstract]
Schedule Of Total Purchase Price Was Allocated To The Acquired Assets Based On Their Relative Fair Values	The total purchase price was allocated to the acquired assets based on their relative fair values, as follows (in thousands): License and acquired intangibles $ 33,569 Acquired research and development inventory expensed from asset acquisition 4,130 Total purchase price $ 37,699

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of income tax expense	The income tax expense (benefit) for the years ended December 31, 2022, 2021, and 2020 consists of (in thousands): 2022 2021 2020 Current - Federal $ 12,858 $ 2,455 $ — Current - State 3,877 1,414 (122 ) Deferred - Federal 4,739 8,620 (29,378 ) Deferred - State 166 696 (3,593 ) $ 21,640 $ 13,185 $ (33,093 )
Reconciliation of income tax expense (Benefit) computed at statutory federal income tax rate	The 21 follows: 2022 2021 2020 Statutory rate 21.0 % 21.0 % 21.0 % State tax 3.1 % 3.4 % 2.2 % Valuation allowance — — (99.4 )% Executive compensation limitation 3.6 % 1.1 % — Tax credit (1.9 )% (0.6 )% (2.4 )% Stock compensation windfall (5.6 )% (0.6 )% — Other 0.5 % 0.7 % (0.4 )% 20.7 % 25.0 % (79.0 )%
Components of deferred tax assets	2022 2021 Deferred tax assets: Net operating loss $ — $ 1,218 Start-up 9,771 10,403 Tax credits — 8,516 Deferred compensation 4,706 3,959 Inventory 296 163 Operating lease liability 953 1,003 Capitalized research 4,255 — Other 96 — Total deferred tax assets 20,077 25,262 Deferred tax liabilities: Prepaid expenses (481 ) (455 ) Right-of (860 ) (936 ) Other — (174 ) Total deferred tax liabilities (1,341 ) (1,565 ) Deferred tax assets, net $ 18,736 $ 23,697

Stock Compensation (Tables)

Stock Compensation (Tables)	12 Months Ended
Stock Compensation (Tables)	Dec. 31, 2022
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation Expense	For the years ended December 31, 2022, 2021 and 2020, the Company recorded stock-based compensation expense as follows (in thousands): 2022 2021 2020 Research and development $ 1,729 $ 1,611 $ 1,585 Selling, general and administrative 6,178 4,462 4,676 Total stock-based compensation $ 7,907 $ 6,073 $ 6,261
Stock option activity under the Company's Plans	Stock option activity under the Company’s Plans for the year ended December 31, 2022 is summarized as follows: Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (in thousands) Outstanding at beginning of year 14,207,728 $ 3.55 Granted 1,386,500 14.82 Exercised or released (3,172,342 ) 3.02 Forfeited or cancelled (112,778 ) 5.73 Expired — — Outstanding at end of year 12,309,108 $ 4.93 3.85 $ 168,222 Exercisable at end of year 8,534,665 $ 3.29 3.00 $ 130,686
Schedule of Other Information Pertaining to Stock Option Activity	Other information pertaining to stock option activity during the years ended December 31, 2022, 2021 and 2020 was as follows: 2022 2021 2020 Weighted–average fair value of granted stock options $ 8.52 $ 3.24 $ 2.33 Total fair value of vested stock options (in thousands) $ 6,096 $ 6,421 $ 5,312 Total intrinsic value of exercised stock options (in thousands) $ 31,881 $ 3,623 $ 325
Summary of Stock Options Awards Based on Certain Assumptions	Assumptions used during the years were as follows: 2022 2021 2020 Risk free interest rate 1.27% to 4.07% 0.34% to 1.18% 0.24% to 1.64% Expected term 4.5 years 4.5 – 4.8 years 4.5 years Expected volatility 68.4% to 69.5% 68.6% to 72.8% 80.5% to 83.7% Expected dividend yield — — — Expected forfeiture rate — — —
Summary of Restricted Stock Unit Activity	Restricted stock unit activity for the year ended December 31, 2022 was as follows; Number of Restricted Stock Units Weighted Average Grant Date Fair Value Nonvested balance at beginning of year 122,839 $ 4.65 Granted 742,500 11.55 Vested (112,839 ) 4.65 Forfeited — — Nonvested balance at end of year 752,500 $ 11.46

Basis of Presentation and Sig_4

Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) $ / shares in Units, $ in Thousands, shares in Millions	12 Months Ended
	Dec. 31, 2022 USD ($) Segment $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares
Summary Of Basis Of Presentation And Significant Accounting Policies [Line Items]
Maximum maturity period of cash and cash equivalent	three months
Non current investments \| $	$ 0	$ 0
Minimum amortization period of compensation cost on straight line basis	1 year
Maximum Amortization Period Of Compensation Cost On Straight Line Basis	3 years
Stock option exercise price range, Minimum \| $ / shares	$ 0.79	$ 0.79	$ 0.79
Stock option exercise price range, Maximum \| $ / shares	$ 7.07	$ 4.64	$ 3.95
Potential equivalent common stock excluded \| shares	1	4.3	7.1
Number of Reportable Segments \| Segment	1
Selling, General and Administrative Expenses [Member]
Summary Of Basis Of Presentation And Significant Accounting Policies [Line Items]
Advertising Expense \| $	$ 3,300	$ 2,900	$ 2,500
Minimum [Member] \| Furniture and Equipment [Member]
Summary Of Basis Of Presentation And Significant Accounting Policies [Line Items]
Useful life of assets	5 years
Minimum [Member] \| Computer Equipment [Member]
Summary Of Basis Of Presentation And Significant Accounting Policies [Line Items]
Useful life of assets	3 years
Minimum [Member] \| Leasehold Improvements [Member]
Summary Of Basis Of Presentation And Significant Accounting Policies [Line Items]
Useful life of assets	5 years
Maximum [Member] \| Furniture and Equipment [Member]
Summary Of Basis Of Presentation And Significant Accounting Policies [Line Items]
Useful life of assets	7 years
Maximum [Member] \| Computer Equipment [Member]
Summary Of Basis Of Presentation And Significant Accounting Policies [Line Items]
Useful life of assets	5 years
Maximum [Member] \| Leasehold Improvements [Member]
Summary Of Basis Of Presentation And Significant Accounting Policies [Line Items]
Useful life of assets	10 years

Basis of Presentation and Sig_5

Basis of Presentation and Significant Accounting Policies - Fair Value Measurement Specific to Assets or Liability (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	$ 0	$ 19,821
Short-term bond funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments		19,821
U.S. Treasuries [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	105,442	140,995
Money market funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	168,853	10,990
Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) [Member] \| Short-term bond funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments		19,821
Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) [Member] \| U.S. Treasuries [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	105,442	140,995
Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) [Member] \| Money market funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 168,853	10,990
Significant Other Observable Inputs (Level 2) [Member] \| U.S. Treasuries [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents		$ 0

Basis of Presentation and Sig_6

Basis of Presentation and Significant Accounting Policies - Schedule Of Reconcile Basic And Dilutive Weighted Average Common Shares (Detail) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Basic weighted average common shares outstanding	103,374,606	103,379,349	103,512,913
Effect of dilutive securities	8,001,025	4,416,236	2,729,360
Dilutive weighted average common shares outstanding	111,375,631	107,795,585	106,242,273

Investments - Additional Inform

Investments - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Investments, Debt and Equity Securities [Abstract]
Realized gains losses from available for sale securities		$ 0	$ 0
Realized losses from sale of available-for-sale securities	$ 762

Investment - Summary of Availab

Investment - Summary of Available-for-Sale Investments by Security type (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Net Investment Income [Line Items]
Estimated Fair Value	$ 105,442	$ 160,816
Gross Unrealized Gains	32	2
Gross Unrealized Losses	0	(196)
Amortized cost	105,410	161,010
U.S. Treasuries - Cash equivalents [Member]
Net Investment Income [Line Items]
Estimated Fair Value	105,442	140,995
Gross Unrealized Gains	32	2
Gross Unrealized Losses	0
Amortized cost	$ 105,410	140,993
Short Term Bond Funds [Member]
Net Investment Income [Line Items]
Estimated Fair Value		19,821
Gross Unrealized Losses		(196)
Amortized cost		$ 20,017

Investment - Estimated Fair Val

Investment - Estimated Fair Values of Available for Sale Securities (Detail) $ in Thousands	Dec. 31, 2022 USD ($)
Investments, Debt and Equity Securities [Abstract]
Due in one year or less	$ 105,442

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) - Summary of Reclassifications out of Accumulated Other Comprehensive Income (loss) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	$ (148)
Other comprehensive gain (loss) before reclassifications	(590)
Amount reclassified from accumulated other comprehensive income	762
Net current period other comprehensive gain (loss)	172	$ (179)	$ 22
Ending balance	$ 24	$ (148)

Inventory - Summary of current

Inventory - Summary of current inventory (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 0	$ 1,769
Work-in-process	5,543	5,172
Finished goods	1,262	929
Total inventory, net	$ 6,805	$ 7,870

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid manufacturing costs	$ 1,147	$ 307
Prepaid tax	44	564
Prepaid insurance	1,224	1,213
Prepaid subscriptions fees	1,202	909
Prepaid research fees	178	452
Prepaid commercialization expenses	198	195
Due from collaborative and licensing arrangements	354	105
Prepaid conference and travel expenses	234	279
Other	577	327
Total prepaid expenses and other current assets	$ 5,158	$ 4,351

Operating Leases - Operating Le

Operating Leases - Operating Leases (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of Operating Leases [Abstract]
Operating lease cost	$ 431	$ 379	$ 300

Operating Leases - Schedule of

Operating Leases - Schedule of Supplemental Cash Flow Information Related To Lease (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows	$ 492	$ 109
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$ 89	$ 80

Operating Leases -Schedule of S

Operating Leases -Schedule of Supplemental Balance Sheet related To Lease (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Disclosure of Operating Leases [Line Items]
Operating lease right-of-use assets	$ 2,770	$ 3,017
Other current liabilities	$ 337	$ 308
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Liabilities, Current	Liabilities, Current
Operating lease liabilities, net of current portion	$ 3,557	$ 3,894
Total operating lease liabilities	$ 3,894	$ 4,202

Operating Leases -Lessee, Opera

Operating Leases -Lessee, Operating Lease, Liability, Maturity (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Disclosure of Operating Leases [Line Items]
2023	$ 506
2024	522
2025	537
2026	553
2027	570
Thereafter	2,027
Total lease payments	4,715
Less imputed interest	(821)
Total	$ 3,894	$ 4,202

Operating Leases - Additional

Operating Leases - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($) ft²	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Disclosure of Operating Leases [Line Items]
Finance Lease Obligations \| $	$ 0
Lessee, Operating Lease, Option to Extend	5
Rent expense \| $	$ 431	$ 379	$ 300
Before agreement of company leased spaces \| ft²	7,800
After agreement of company leased spaces \| ft²	10,700
Weighted average remaining lease term	8 years 3 months 18 days	9 years 3 months 18 days
Weighted average discount rate	4.51%	4.51%
Maximum [Member]
Disclosure of Operating Leases [Line Items]
Lessee, Operating Lease, Option to Terminate	7.6
Minimum [Member]
Disclosure of Operating Leases [Line Items]
Lessee, Operating Lease, Option to Terminate	6

Property and Equipment, Net - P

Property and Equipment, Net - Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Less: Accumulated depreciation	$ (406)	$ (275)
Total property and equipment, net	847	959
Computer equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	51	51
Furniture and equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	222	203
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 980	$ 980

License and Acquired Intangib_3

License and Acquired Intangibles, Net - Schedule of Finite Lived Intangible Assets (Detail) $ in Thousands	Dec. 31, 2022 USD ($)
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 33,569
Accumulated Amortization	1,098
Net Carrying Value	32,471
License and Acquired Intangibles for RUZURGI [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	33,569
Accumulated Amortization	1,098
Net Carrying Value	$ 32,471

License and Acquired Intangib_4

License and Acquired Intangibles, Net - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived intangible asset, useful life	14 years 6 months
Finite lived intangible asset expected amortization per year	$ 2,300,000
Amortization of intangible assets	1,098,000
Impairment charges recognized on definite-lived intangibles	$ 0	$ 0

Accrued Expenses and Other Li_3

Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued preclinical and clinical trial expenses	$ 479	$ 659
Accrued professional fees	1,619	2,391
Accrued compensation and benefits	5,132	4,035
Accrued license fees	20,444	12,819
Accrued purchases	154	2,045
Operating lease liability	337	308
Accrued variable consideration	3,381	1,716
Accrued income tax	8,702	79
Due to licensor	13,127	0
Other	238	243
Current accrued expenses and other liabilities	53,613	24,295
Lease liability – non-current	3,557	3,894
Due to licensor – non-current	14,064	0
Non-current accrued expenses and other liabilities	17,621	3,894
Total accrued expenses and other liabilities	$ 71,234	$ 28,189

Collaborative and Licensing A_2

Collaborative and Licensing Arrangements - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Collaborative Arrangements [Line Items]
Period of collaboration agreement	10 years
Research and development expenses	$ 19,789,000	$ 16,936,000	$ 16,497,000
Milestone payments income	0	0	0
KYE Pharmaceuticals [Member] \| Selling, General and Administrative Expenses [Member]
Collaborative Arrangements [Line Items]
Expenses incurred in connection with collaboration agreement	0	0	0
Dydo Pharma Inc [Member]
Collaborative Arrangements [Line Items]
Milestone payments income	0
Revenues		2,900,000
Dydo Pharma Inc [Member] \| Non Refundable Upfront License Fees [Member]
Collaborative Arrangements [Line Items]
Revenues		2,700,000
Collaborative Arrangement [Member]
Collaborative Arrangements [Line Items]
Milestone payments	2,000,000
Revenues	0	0	0
Collaborative Arrangement [Member] \| Product revenue, net [Member]
Collaborative Arrangements [Line Items]
Revenues	500,000
Collaborative Arrangement [Member] \| Research and Development Expense [Member]
Collaborative Arrangements [Line Items]
Research and development expenses	$ 0	$ 45,000	$ 4,200

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - License and Asset Purchase Agreement [Member] $ in Millions	Jul. 11, 2022 USD ($)
Commitments [Line Items]
Purchase price of an asset acquisition	$ 30
Upfront payment related to asset acquisition	$ 10
Percentage of the consideration paid by a third party to acquire that voucher	50%
Calendar Years 2022 Through 2025 [Member]
Commitments [Line Items]
Percentage of annual royalty on the Company's net sales	1.50%
Minimum royalty amount	$ 3
Calendar Year 2026 [Member]
Commitments [Line Items]
Percentage of annual royalty on the Company's net sales	2.50%
Minimum royalty amount	$ 5

Agreements - Additional Informa

Agreements - Additional Information (Detail) - USD ($) $ in Thousands						12 Months Ended
	Jul. 11, 2026	Jul. 11, 2025	Jul. 11, 2024	Jul. 11, 2023	Jul. 11, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
License Agreement [Line Items]
Percentage of royalty on net sales						3.50%
Research and development expenses						$ 19,789	$ 16,936	$ 16,497
License Agreement with BioMarin [Member]
License Agreement [Line Items]
Date on which strategic collaboration is entered into						Oct. 26, 2012
Royalty agreement period						7 years
Net sales royalty threshold						$ 100,000
License Agreement with BioMarin [Member] \| Minimum [Member]
License Agreement [Line Items]
Percentage of royalty on net sales						7%
License Agreement with BioMarin [Member] \| Maximum [Member]
License Agreement [Line Items]
Percentage of royalty on net sales						10%
License Agreement For RUZURGI [Member]
License Agreement [Line Items]
Date on which strategic collaboration is entered into						Jul. 11, 2022
Minimum royalty	$ 5,000	$ 3,000	$ 3,000	$ 3,000
Research and development expenses						$ 4,100
Up front payment					$ 10,000
Asset acquisition purchase price consideration			$ 10,000	$ 10,000
License Agreement For RUZURGI [Member] \| Minimum [Member]
License Agreement [Line Items]
Percentage of minimum royalty payable to net sales						1.25%
License Agreement For RUZURGI [Member] \| Maximum [Member]
License Agreement [Line Items]
Percentage of maximum royalty payable to net sales						2.50%

Agreements - Schedule Of Total

Agreements - Schedule Of Total Purchase Price Was Allocated To The Acquired Assets Based On Their Relative Fair Values (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Schedule Of Total Purchase Price Was Allocated To The Acquired Assets Based On Their Relative Fair Values [Line Items]
License and acquired intangibles	$ 33,569
Acquired research and development inventory expensed from asset acquisition	4,130
Total purchase price	$ 37,699

Income Taxes - Schedule of inco

Income Taxes - Schedule of income tax expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Current - Federal	$ 12,858	$ 2,455
Current - State	3,877	1,414	$ (122)
Deferred - Federal	4,739	8,620	(29,378)
Deferred - State	166	696	(3,593)
Total income tax expense	$ 21,640	$ 13,185	$ (33,093)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Line Items]
Deferred tax assets, net	$ 20,077	$ 25,262
Unrecognized tax benefits income tax penalties accrued		0
State and Local Jurisdiction [Member]
Income Tax Disclosure [Line Items]
Net operating loss carryforwards	$ 0	$ 28,000

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of Income Tax Expense (Benefit) Computed at Statutory Federal Income Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Statutory rate	21%	21%	21%
State tax	3.10%	3.40%	2.20%
Valuation allowance	0%	0%	(99.40%)
Executive compensation limitation	3.60%	1.10%	0%
Tax credit	(1.90%)	(0.60%)	(2.40%)
Stock compensation windfall	(5.60%)	(0.60%)
Other	0.50%	0.70%	(0.40%)
Reconciliation of income tax expense (benefit)	20.70%	25%	(79.00%)

Income Taxes - Components of De

Income Taxes - Components of Deferred Tax Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred Tax Assets [Abstract]
Net operating loss	$ 0	$ 1,218
Start-up costs	9,771	10,403
Tax credits	0	8,516
Deferred compensation	4,706	3,959
Inventory	296	163
Operating lease liability	953	1,003
Capitalized research	4,255
Other	96	0
Total deferred tax assets	20,077	25,262
Deferred tax liabilities:
Prepaid expenses	(481)	(455)
Right-of use asset	(860)	(936)
Other	0	(174)
Total deferred tax liabilities	(1,341)	(1,565)
Deferred tax assets, net	$ 18,736	$ 23,697

Stockholders' Equity (Preferred

Stockholders' Equity (Preferred Stock and Common Stock) - Additional Information (Detail)	Dec. 31, 2022 Vote $ / shares shares	Dec. 31, 2021 $ / shares shares
Stockholders Equity [Line Items]
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, par value \| $ / shares	$ 0.001	$ 0.001
Preferred stock, shares outstanding	0	0
Common stock, shares authorized	200,000,000	200,000,000
Common stock, par value \| $ / shares	$ 0.001	$ 0.001
Common stock, shares issued	105,263,031	102,992,913
Common stock, shares outstanding	105,263,031	102,992,913
Number of votes entitled for each share of common stock \| Vote	1

Stockholders' Equity ( Share Re

Stockholders' Equity ( Share Repurchases ) - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2021
Stockholders Equity [Line Items]
Aggregate purchase price	$ 6,907	$ 12,089
Average price per share	$ 6.91	$ 5.47
Common Stock [Member]
Stockholders Equity [Line Items]
Aggregate share repurchased	(1,000,000)	(2,208,292)
Share Purchase Program [Member] \| Common Stock [Member]
Stockholders Equity [Line Items]
Share repurchase program, authorised			$ 40,000

Stockholders' Equity (2020 Shel

Stockholders' Equity (2020 Shelf Registration Statement) - Additional Information (Detail) $ in Millions	Jul. 23, 2020 USD ($)
2020 Shelf Registration Statement [Member]
Stockholders' Equity [Line Items]
Maximum dollar amount of common stock to be issued under shelf registration statement	$ 200

Stockholders' Equity (Stockhold

Stockholders' Equity (Stockholder Rights Plan) - Additional Information (Detail) - $ / shares	Sep. 19, 2016	Sep. 20, 2011
Series A Preferred Stock [Member]
Stockholders Equity [Line Items]
Preferred Stock Purchase Price		$ 7.8
Stockholder Rights Plan [Member]
Stockholders Equity [Line Items]
Minimum percentage of outstanding stock acquired by a person or group to trigger Shareholder Rights Plan		17.50%
Warrants exercise price		$ 7.8
Stockholders Rights Plan redemption price of right		$ 0.001
Class of warrant or right expiration date, Extended	Sep. 20, 2019
Certificate Of Designation [Member] \| Series A Preferred Stock [Member]
Stockholders Equity [Line Items]
Junior participating preferred stock shares issued available for issuance under rights agreement, initial	500,000
Junior participating preferred stock shares issued available for issuance under rights agreement, amended	1,500,000

Stock Compensation - Stock-Base

Stock Compensation - Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 7,907	$ 6,073	$ 6,261
Research and Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	1,729	1,611	1,585
Selling, General and Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 6,178	$ 4,462	$ 4,676

Stock Compensation - Additional

Stock Compensation - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options exercised	3,172,342
Proceeds from exercise of stock options	$ 9,569	$ 4,099	$ 758
Common stock unit granted	1,386,500
Expected dividend rate	0%	0%	0%
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option contractual term	7 years
Stock Option [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation, vesting period	1 year
Stock Option [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation, vesting period	3 years
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-cash stock-based compensation expense	$ 1,600	$ 500	$ 600
Two Thousand Eighteen Stock Incentive Plan [Member] \| Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares reserved for issuance under the Plan	15,000,000
Common stock shares available for future issuance under the Plan	2,691,791
Two Thousand Eighteen Stock Incentive Plan [Member] \| Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation, vesting period	3 years
Options to Purchase Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options exercised	3,172,342	1,328,936	281,762
Proceeds from exercise of stock options	$ 9,600	$ 4,100	$ 800
Stock option granted, contractual term	7 years	7 years	7 years
Common stock unit granted	1,386,500	2,330,000	2,715,000
Unrecognized compensation expense related to non-vested stock compensation awards granted under the Plan	$ 16,700
Expected remaining weighted average vesting period	2 years 6 months 10 days
Non-cash stock-based compensation expense	$ 6,300	$ 5,500	$ 5,700
Expected dividend rate	0%

Stock Compensation - Summary of

Stock Compensation - Summary of Stock Option Activity under the Company's Plan (Detail) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($) $ / shares shares
Share-based Payment Arrangement [Abstract]
Number of options, Outstanding at beginning of year \| shares	14,207,728
Number of options, Granted \| shares	1,386,500
Number of options, Exercised or released \| shares	(3,172,342)
Number of options, Forfeited or cancelled \| shares	(112,778)
Number of options, Expired \| shares	0
Number of options, Outstanding at end of year \| shares	12,309,108
Number of options, Exercisable at end of year \| shares	8,534,665
Weighted average exercise price, Outstanding at beginning of year \| $ / shares	$ 3.55
Weighted average exercise price, Granted \| $ / shares	14.82
Weighted average exercise price, Exercised or released \| $ / shares	3.02
Weighted average exercise price, Forfeited or cancelled \| $ / shares	5.73
Weighted average exercise price, Expired \| $ / shares	0
Weighted average exercise price, Outstanding at end of year \| $ / shares	4.93
Weighted average exercise price, Exercisable at end of year \| $ / shares	$ 3.29
Weighted Average Remaining Contractual Term (Years), Outstanding at end of year	3 years 10 months 6 days
Weighted Average Remaining Contractual Term (Years), Exercisable at end of year	3 years
Aggregate Intrinsic value, Outstanding at end of year \| $	$ 168,222
Aggregate Intrinsic value, Exercisable at end of year \| $	$ 130,686

Stock Compensation - Schedule o

Stock Compensation - Schedule of Other Information Pertaining to Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Weighted-average fair value of granted stock options	$ 8.52	$ 3.24	$ 2.33
Total fair value of vested stock options	$ 6,096	$ 6,421	$ 5,312
Total intrinsic value of exercised stock options	$ 31,881	$ 3,623	$ 325

Stock Compensation - Summary _2

Stock Compensation - Summary of Stock Options Awards Based on Certain Assumptions (Detail)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate, Minimum	1.27%	0.34%	0.24%
Risk free interest rate, Maximum	4.07%	1.18%	1.64%
Expected dividend yield	0%	0%	0%
Expected forfeiture rate	0%	0%	0%
Expected term	4 years 6 months		4 years 6 months
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	68.40%	68.60%	80.50%
Expected term		4 years 6 months
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	69.50%	72.80%	83.70%
Expected term		4 years 9 months 18 days

Stock Compensation - Summary _3

Stock Compensation - Summary of Restricted Stock Unit Activity (Detail) - Restricted Stock Units (RSUs) [Member]	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Schedule Of Restricted Stock Activity [Line Items]
Nonvested balance at beginning of year \| shares	122,839
Granted \| shares	742,500
Vested \| shares	(112,839)
Forfeited \| shares	0
Nonvested balance at end of year \| shares	752,500
Nonvested Weighted Average Grant Date Fair Value balance at beginning of year \| $ / shares	$ 4.65
Weighted Average Grant Date Fair Value, Granted \| $ / shares	11.55
Weighted Average Grant Date Fair Value, Vested \| $ / shares	4.65
Weighted Average Grant Date Fair Value, Forfeited \| $ / shares	0
Nonvested Weighted Average Grant Date Fair Value balance at end of year \| $ / shares	$ 11.46

Benefit Plan - Additional Infor

Benefit Plan - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Retirement Benefits [Abstract]
Employees contribution of pre-tax annual compensation	15%
Discretionary matching contributions of employee contributions of an employee's gross salary	4%
Contributions	$ 0.5	$ 0.5	$ 0.5

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - Subsequent Event [Member] $ in Millions	Jan. 24, 2023 USD ($)
Subsequent Event [Line Items]
Upfront Cash Payment	$ 160
Reimbursement Of Certain Prepayments	1.6
Contingent Payment	$ 25